Similar articles

• Reply to Verlingue, Koscielny and Ferté.

  Litière S, De Vries EG, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST committee. Litière S, et al. Eur J Cancer. 2014 Nov;50(16):2889-91. doi: 10.1016/j.ejca.2014.08.001. Epub 2014 Sep 15. Eur J Cancer. 2014. PMID: 25219450 No abstract available.
• The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.

  Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee. Litière S, et al. Eur J Cancer. 2014 Jul;50(10):1847-1853. doi: 10.1016/j.ejca.2014.03.014. Epub 2014 Apr 10. Eur J Cancer. 2014. PMID: 24726734
• Non-target progression--the fine line between objectivity and subjectivity.

  Lheureux S, Wilson MK, O'Malley M, Sinaei M, Oza AM. Lheureux S, et al. Eur J Cancer. 2014 Dec;50(18):3271-2. doi: 10.1016/j.ejca.2014.08.021. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25450948 No abstract available.
• Targeting VEGF in cancer therapy.

  Donovan EA, Kummar S. Donovan EA, et al. Curr Probl Cancer. 2006 Jan-Feb;30(1):7-32. doi: 10.1016/j.currproblcancer.2005.11.001. Curr Probl Cancer. 2006. PMID: 16443047 Review. No abstract available.
• [Medical oncology].

  Aapro MS. Aapro MS. Rev Med Suisse. 2005 Jan 5;1(1):59-67. Rev Med Suisse. 2005. PMID: 15773200 Review. French.